Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | USP2 | O75604 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759441 | 0.92 | BDKRB1 (0.84) | BDKRB1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL5629162 | 0.88 | BDKRB1 (0.78) | BDKRB1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4716342 | 0.87 | BDKRB1 (0.77) | BDKRB1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4717507 | 0.86 | BDKRB1 (0.76) | BDKRB1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4717762 | 0.85 | BDKRB1 (0.74) | BDKRB1CYP3A4CYP1A2USP2MAPK1 | |
| SCHEMBL4712523 | 0.84 | BDKRB1 (0.72) | BDKRB1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4715984 | 0.83 | BDKRB1 (0.71) | BDKRB1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL5628537 | 0.82 | BDKRB1 (0.70) | BDKRB1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4714147 | 0.81 | BDKRB1 (0.69) | BDKRB1CYP3A4CYP1A2TSHRALDH1A1 | |
| SCHEMBL4717607 | 0.81 | BDKRB1 (0.68) | BDKRB1CYP3A4CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344176-A1 | USE OF BRADYKININ B1 RECEPTOR ANTAGONISTS IN INTESTINAL FIBROSIS TREATMENT | Jerini AG (DE) | 2011-07-20 | — | — | EP | claimed |
| WO-2010031577-A1 | USE OF BRADYKININ B1 RECEPTOR ANTAGONISTS IN INTESTINAL FIBROSIS TREATMENT | JERINI AG (DE) | 2010-03-25 | — | — | WO | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| US-20260062760-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | MOREHOUSE SCHOOL OF MEDICINE (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260055473-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | MOREHOUSE SCHOOL OF MEDICINE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20230340604-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | MOREHOUSE SCHOOL OF MEDICINE | 2023-10-26 | — | — | US | disclosed |
| EP-2344176-A1 | USE OF BRADYKININ B1 RECEPTOR ANTAGONISTS IN INTESTINAL FIBROSIS TREATMENT | Jerini AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010031577-A1 | USE OF BRADYKININ B1 RECEPTOR ANTAGONISTS IN INTESTINAL FIBROSIS TREATMENT | JERINI AG (DE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010031577-A1 | USE OF BRADYKININ B1 RECEPTOR ANTAGONISTS IN INTESTINAL FIBROSIS TREATMENT | JERINI AG (DE) | 2010-03-25 | — | — | WO | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062760-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | HNRNPH3, HNRNPH1, UTRN | BDKRB1 3686/4885CYP3A4 4867/4885CYP2C9 4875/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | BDKRB1 1/4885CYP3A4 3178/4885CYP2C9 3256/4885 |
| US-20260055473-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | HNRNPH3, MYCBP2, HNRNPH1 | BDKRB1 3641/4885CYP3A4 4873/4885CYP2C9 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.